Anticancer Res. 2001 Jul-Aug;21(4A):2477-82.
Antitumor activity of cytotropic heterogeneous molecular lipids (CHML) on human breast cancer xenograft in nude mice.
Zhan Q, Zhao SC, Xu Z.
Source
Department of Radiation Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA 15213, USA.
Abstract
Cytotropic heterogeneous molecular lipid (CHML), which is a new anticancer agent with US patent number 5,260,067, has recently been shown to suppress tumor cell growth in multiple tumor lines and induce apoptosis in vitro (1). These results indicate that CHML may be an effective antitumor agent. In the present study, using both local injection and intravenous injection, we have investigated the suppressive effect of CHML on human breast caner cells MCF-7 xenograft in nude mice. In the local injection, CHML was introduced into nude mice implanted with human breast cancer xenograft at doses of 25 mg/tumor area (cm2), 35 mg/tumor area (cm2), or 50 mg/tumor area (cm2), once every two days, total 3 times. The inhibition of tumor growth was 81.3%, 93.8% and 100%, respectively. In the intravenous injection, the nude mice bearing MCF-7 xenografts were treated with CHML at 10 mg/kg/day, or 15 mg/kg/day, or 20 mg/kg/day, once a day, total 7 days, the growth inhibition of tumor area was 58.1%, 77.4%, and 83.9%, respectively. At the same time, the toxicity of CHML was determined through examining the number of the white blood cell (WBC) and the activity of the serum glutamic-pyruvic transaminase (SGPT). However, no evident alterations of WBC and SGPT were detected in all animals treated with CHML, suggesting that CHML has little toxicity on nude mice. Taken together, these results indicate that CHML is an effective agent that suppresses breast tumor growth and suggest the possibility of using CHML in the clinical trial in the near future.
PMID: 11724310
MeSH Terms, Substances
Willdonggang 发表于 2012-6-6 04:16 static/image/common/back.gif
Anticancer Res. 2001 Jul-Aug;21(4A):2477-82.
Antitumor activity of cytotropic heterogeneous molecul ...
有谁帮忙翻译一下。
本帖最后由 Willdonggang 于 2012-6-6 15:02 编辑
暖阳 发表于 2012-6-6 12:05 static/image/common/back.gif
有谁帮忙翻译一下。
亲细胞非均质分子脂质（CHML），美国专利号码5260067，这是一种新的抗癌药物，最近已被证明能抑制多种肿瘤细胞的生长和诱导凋亡在体外（1）。这些结果表明，CHML可能是一种有效的抗肿瘤剂。在本研究中，采用局部注射和静脉注射，我们已经调查CHML对人乳腺癌MCF-7裸鼠移植瘤的抑制作用。人类乳腺癌移植在裸鼠体内，局部注射CHML，剂量为25毫克/肿瘤面积（平方厘米），35毫克/肿瘤面积（cm2），或50毫克/肿瘤面积（平方厘米），两天一次，共3次。抑制肿瘤的生长，分别为81.3％，93.8％和100％。静脉注射，MCF-7移植瘤裸鼠治疗CHML在10毫克/公斤/天，或15毫克/公斤/天，或20毫克/公斤/天，每天一次，共7天，生长抑制肿瘤面积分别为58.1％，77.4％和83.9％。CHML毒性是通过审查的白血细胞（WBC）和血清谷丙转氨酶（SGPT）测定。发现没有明显毒性。这些结果表明，CHML是一个有效的药剂，抑制乳腺肿瘤的生长, 有可能在不久的将来在临床试验中使用CHML。
暖阳，看到小老鼠是怎么用的了吗？ 你使用的剂量是什么？ 怎么用的？
朋友，该药出现到如今已有15年了，使用上和配方组合上也不断更新，我第一疗程是肝动脉缓释用药，第二三疗程是动静脉联合双向联合缓释用药，目前第三疗程第六天，疗效观察中。。。。。。
望有福之人早日康复~!
精灵 发表于 2012-7-30 20:59 static/image/common/back.gif
望有福之人早日康复~!
谢谢精灵！！
暖阳 发表于 2012-8-18 19:02 static/image/common/back.gif
谢谢精灵！！
目前因肝动脉左分支形成血栓，肝左叶已长满肿瘤，肝右叶目前控制不错，我准备把左肝全部拿掉。
祝福！
暖阳 发表于 2012-8-18 19:22 static/image/common/back.gif
目前因肝动脉左分支形成血栓，肝左叶已长满肿瘤，肝右叶目前控制不错，我准备把左肝全部拿掉。
祝福暖阳一切顺利！
雪绒花 发表于 2012-8-19 23:07 static/image/common/back.gif
祝福暖阳一切顺利！
谢谢雪花姐的祝福！